Product Description
Mechanisms of Action: HP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Innovative Molecules GmbH
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for IM-250](https://pryzm-maps.s3.us-west-2.amazonaws.com/40current_maps.png)
Countries in Clinic: Germany
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Herpes Simplex
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
IM-101 | P1 |
Recruiting |
Herpes Simplex |
2024-05-28 |